Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660590 | 0.87 | EGLN1 (0.66) | EGLN1ALDH1A1ALDH1A3PTGS1PTGS2 | |
| SCHEMBL30977270 | 0.87 | EGLN1 (0.66) | EGLN1ALDH1A1ALDH1A3PTGS1PTGS2 | |
| SCHEMBL299158 | 0.87 | HRH4 (0.58) | EGLN1ALDH1A1PTGS1PTGS2RAB9A | |
| SCHEMBL741720 | 0.85 | HRH4 (0.57) | EGLN1ALDH1A1PTGS1PTGS2RAB9A | |
| SCHEMBL21001625 | 0.84 | EGLN1 (0.67) | EGLN1ALDH1A1ALDH1A3PTGS1PTGS2 | |
| SCHEMBL21033155 | 0.83 | EGLN1 (0.53) | EGLN1ALDH1A1ALDH1A3PTGS1PTGS2 | |
| SCHEMBL3499809 | 0.81 | EGLN1 (1.00) | EGLN1ALDH1A1ALDH1A3NR4A2CYP2C9 | |
| SCHEMBL21033157 | 0.81 | ALDH1A3 (0.60) | EGLN1ALDH1A1ALDH1A3PTGS1PTGS2 | |
| SCHEMBL3498830 | 0.81 | PTGS1 (0.51) | EGLN1PTGS1PTGS2RAB9ANPC1 | |
| SCHEMBL3499130 | 0.80 | GABRA2 (0.62) | EGLN1PTGS2RAB9AGABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255684-B | CD4 enhancement+Compounds for T cell differentiation into Th9 cells | 广州医科大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118255684-A | CD4 enhancement+Compounds for T cell differentiation into Th9 cells | 广州医科大学 | 2024-06-28 | — | — | CN | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | EGLN1 1231/4885ALDH1A1 3047/4885ALDH1A3 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.